Philip Liebson to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Philip Liebson has written about Randomized Controlled Trials as Topic.
Connection Strength
0.295
-
ENHANCE and ONTARGET. Prev Cardiol. 2008; 11(3):179-82.
Score: 0.066
-
Muraglitazar and the FDA: what constitutes drug safety? Prev Cardiol. 2006; 9(2):110-4.
Score: 0.057
-
VALIANT and EUROPA. Prev Cardiol. 2004; 7(1):42-4.
Score: 0.050
-
VISP and INVEST. Prev Cardiol. 2004; 7(2):93-6.
Score: 0.050
-
ASAP and ANTIBIO. Prev Cardiol. 2003; 6(3):166-8.
Score: 0.046
-
Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective. Cardiol Rev. 2004 Nov-Dec; 12(6):287-98.
Score: 0.013
-
Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapy. Am J Cardiol. 2004 Jun 03; 93(11A):32C-48C.
Score: 0.013